Newbury Pharmaceuticals AB (NEWBRY) Fair Value & Analysis
Healthcare · SE · Market cap 76.0M SEK (≈ $7.9M) · ISIN SE0015244884
What is Newbury Pharmaceuticals AB really worth?
Below-average quality, and trading another 82% above our fair value of kr 1.38.
Risks
Fair value as of: Aug 28, 2026
From 1 valuation models · updated 4 days ago
Share price −10.4% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (kr 1.70). The favourable scenario is already priced in.
- Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (kr 0.8925 to kr 1.70) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 28, 2026.
How to read this chart
55‑month range kr 0.8000 – kr 12.60 · fair‑value band kr 0.8925 – kr 1.70 · the kr 2.51 price screens above the kr 1.38 fair value. Dashed = 300-day average. As of Aug 28, 2026.
Analysis
Newbury Pharmaceuticals AB (NEWBRY) currently trades at kr 2.51, while our model-based Fair Value estimate is kr 1.38, implying the stock looks roughly 82.3% overvalued today. The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector. How firm this estimate is: it rests on 1 models at a data quality of 91/100, which puts the evidence level at low.
Over the trailing twelve months, Newbury Pharmaceuticals AB generated revenue of 32.8M SEK at a net margin of −86.9%. Revenue declined 32.0% year over year. It earns a return on equity of −74.9%. The balance sheet holds a net cash position of 15.3M SEK. Fundamentals as of Aug 28, 2026
Our scenario range runs from kr 0.8925 (bear case) to kr 1.70 (bull case); at kr 2.51, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 24% below its 52-week high and 230% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −45%, NEWBRY screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 1 models by family
Notify me when NEWBRY reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 28, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 38 · Market factors (momentum, volatility) 43
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden and the Scandinavian market. It offers oncology, rare diseases, neurology, and other treatment products. Newbury Pharmaceuticals AB (publ) was incorporated in 2020 and is based in Lund, Sweden.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Newbury Pharmaceuticals AB reported revenue of 36.8M SEK in FY2024 versus 2.8M SEK in FY2021, a compound +135.2%/yr. Reported net income was −20.6M SEK in FY2025.
NEWBRY screens 82% overvalued. Compare with Merck KGaA →
Peer Group
Drug Manufacturers - Specialty & Generic · 636 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 28, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Merck KGaA MRK | €140.25 | €106.48 | −24% |
| Takeda Pharmaceutical Company TAK | $18.03 | $11.11 | −38% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | −52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | −49% |
| Galderma Group GALD | CHF 178.55 | CHF 55.07 | −69% |
| Haleon plc HLN | $10.11 | $7.64 | −24% |
| Teva Pharmaceutical Industries Limited TEVA | $37.92 | $15.33 | −60% |
| Sandoz Group SDZ | CHF 70.66 | CHF 39.21 | −45% |
| Zoetis Inc ZTS | $77.52 | $104.88 | +35% |
| Hansoh Pharmaceutical Group 3692 | HK$33.50 | HK$16.14 | −52% |
Compare Newbury Pharmaceuticals AB with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Newbury Pharmaceuticals AB (NEWBRY) overvalued or undervalued?
What is the fair value of NEWBRY?
What is the quality score of NEWBRY?
What is the revenue of Newbury Pharmaceuticals AB (NEWBRY)?
What is the net profit margin of NEWBRY?
Watch Newbury Pharmaceuticals AB in the live analysis
One click puts Newbury Pharmaceuticals AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.